Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation : Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France)
COVERAGE France is Multicenter, randomized, controlled clinical trial with for each drug :A safety study pilot phase.An efficacy study phase. The data collected during the pilot phase, combined with new external data that emerged during the period, will be used to position treatments for the efficacy phase.Pilot phase will evaluate the tolerance of experimental treatments for drugs given for the first time ("first in home-based care") in ambulatory individuals with COVID-19 with aggravating risk factors.Efficacy Phase: To estimate the effectiveness of experimental ambulatory treatments, compared to vitamin supplementation, in reducing the risk of hospitalization, oxygen therapy indication or death in ambulatory individuals with COVID-19 with aggravating risk factors.The trial is a national platform with the vocation to open as many centers as possible, subject to criteria set by the Scientific Advisory Board..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ClinicalTrials.gov - (2022) vom: 04. Feb. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 22, 2020, Last downloaded: ClinicalTrials.gov processed this data on February 14, 2022, Last updated: February 16, 2022 |
|---|
| Study ID: |
NCT04356495 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003367347 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003367347 | ||
| 003 | DE-627 | ||
| 005 | 20230425210419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003367347 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04356495 | ||
| 035 | |a (UBBS_Klinische_Studien)CHUBX 2020/12 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation |b Randomized Trial to Evaluate the Safety and Efficacy of Outpatient Treatments to Reduce the Risk of Worsening in Individuals With COVID-19 With Risk Factors (COVERAGE France) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 22, 2020, Last downloaded: ClinicalTrials.gov processed this data on February 14, 2022, Last updated: February 16, 2022 | ||
| 520 | |a COVERAGE France is Multicenter, randomized, controlled clinical trial with for each drug :A safety study pilot phase.An efficacy study phase. The data collected during the pilot phase, combined with new external data that emerged during the period, will be used to position treatments for the efficacy phase.Pilot phase will evaluate the tolerance of experimental treatments for drugs given for the first time ("first in home-based care") in ambulatory individuals with COVID-19 with aggravating risk factors.Efficacy Phase: To estimate the effectiveness of experimental ambulatory treatments, compared to vitamin supplementation, in reducing the risk of hospitalization, oxygen therapy indication or death in ambulatory individuals with COVID-19 with aggravating risk factors.The trial is a national platform with the vocation to open as many centers as possible, subject to criteria set by the Scientific Advisory Board. | ||
| 650 | 2 | |a Coronavirus Infections | |
| 650 | 4 | |a Medical Condition: Corona Virus Infection, Sars-CoV2 | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Completed | |
| 650 | 4 | |a Phase: Phase 2, Phase 3 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2022) vom: 04. Feb. |
| 773 | 1 | 8 | |g year:2022 |g day:04 |g month:02 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04356495 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 04 |c 02 | ||